Analytical Data
-
Gene name
Cathepsin A
- Application
-
Alternative Names
CTS-A; GLB2; GSL; NGBE; PPCA; PPGB; Protective Protein For Beta-Galactosidase; Galactosialidosis; Carboxypeptidase C; Carboxypeptidase L
-
Species
Pig
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
F1SC70
-
Expression Region
Ala44~Tyr493
-
Molecular Weight
60kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Prostatic Acid Phosphatase (PAP), an enzyme prominently expressed in the prostate gland, plays a significant role in the context of prostate cancer diagnosis and treatment. It has garnered attention for its potential as a biomarker for prostate cancer, particularly in advanced disease stages. Historically, PAP levels have been utilized to monitor disease progression and treatment response. However, the complexities surrounding its role in pathophysiology necessitate a deeper understanding of its structure and function. Recent advances in recombinant protein technology enable the production of ACPP (recombinant Prostatic Acid Phosphatase), facilitating the exploration of its biochemical properties and interactions at a molecular level. This recombinant form serves as a valuable tool for elucidating enzymatic mechanisms and developing assays that can enhance diagnostic accuracy. Moreover, investigations into the therapeutic applications of ACPP, including its potential role in immunotherapy and targeted treatments, highlight the importance of this enzyme in clinical oncology research. By examining ACPP at a molecular level, researchers aim to unlock new insights into prostate cancer biology, improve diagnostic methodologies, and identify novel therapeutic targets, ultimately contributing to better healthcare outcomes for patients affected by prostate cancer.
